{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T20:41:45Z","timestamp":1780087305188,"version":"3.54.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"am","delay-in-days":314,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.hoc.2023.05.017","type":"journal-article","created":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T19:23:23Z","timestamp":1687634603000},"page":"1107-1124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Chimeric Antigen Receptor T Cells in Hodgkin and T-Cell Lymphomas"],"prefix":"10.1016","volume":"37","author":[{"given":"Ibrahim N.","family":"Muhsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LaQuisa C.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A.","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.hoc.2023.05.017_bib1","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"ECHELON-1 Study Group. Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.hoc.2023.05.017_bib2","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"Chen","year":"2016","journal-title":"Blood"},{"issue":"9980","key":"10.1016\/j.hoc.2023.05.017_bib3","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.hoc.2023.05.017_bib4","first-page":"1116","article-title":"An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30","volume":"58","author":"Hombach","year":"1998","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.hoc.2023.05.017_bib5","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1182\/blood-2006-11-059139","article-title":"Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease","volume":"110","author":"Savoldo","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.05.017_bib6","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3389\/fonc.2019.00126","article-title":"Chimeric Antigen Receptors for T-Cell Malignancies","volume":"9","author":"Scherer","year":"2019","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2023.05.017_bib7","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1186\/s13287-021-02595-0","article-title":"CAR-T cell therapy in T-cell malignancies: Is success a low-hanging fruit?","volume":"12","author":"Safarzadeh Kozani","year":"2021","journal-title":"Stem Cell Res Ther"},{"issue":"7","key":"10.1016\/j.hoc.2023.05.017_bib8","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin\u2019s lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.hoc.2023.05.017_bib9","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1182\/bloodadvances.2021005304","article-title":"Adoptive T-cell therapy for Hodgkin lymphoma","volume":"5","author":"Ho","year":"2021","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.hoc.2023.05.017_bib10","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1182\/blood-2011-08-371971","article-title":"Adoptive immunotherapy with unselected or EBV-specific T\u00a0cells for biopsy-proven EBV1 lymphomas after allogeneic hematopoietic cell transplantation","volume":"119","author":"Doubrovina","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2023.05.017_bib11","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","article-title":"Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients","volume":"115","author":"Heslop","year":"2010","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2023.05.017_bib12","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1084\/jem.20040890","article-title":"Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease","volume":"200","author":"Bollard","year":"2004","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.hoc.2023.05.017_bib13","doi-asserted-by":"crossref","unstructured":"van der Weyden C.A., Pileri S.A., Feldman A.L., et al., Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions, Blood Cancer J, 2017;7(9): e603.","DOI":"10.1038\/bcj.2017.85"},{"key":"10.1016\/j.hoc.2023.05.017_bib14","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1038\/sj.onc.1205337","article-title":"Ligandindependent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin\u2013Reed\u2013Sternberg cells","volume":"21","author":"Horie","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.hoc.2023.05.017_bib15","doi-asserted-by":"crossref","first-page":"510","DOI":"10.2353\/ajpath.2008.070858","article-title":"CD30- induced signaling is absent in Hodgkin's cells but present in anaplastic large cell lymphoma cells","volume":"172","author":"Hirsch","year":"2008","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.hoc.2023.05.017_bib16","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12885-019-5415-9","article-title":"Challenges of driving CD30-directed CAR-T cells to the clinic","volume":"19","author":"Grover","year":"2019","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.hoc.2023.05.017_bib17","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","article-title":"Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial","volume":"23","author":"Wang","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.hoc.2023.05.017_bib18","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1172\/JCI94306","article-title":"Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes","volume":"127","author":"Ramos","year":"2017","journal-title":"J\u00a0Clin Invest"},{"issue":"32","key":"10.1016\/j.hoc.2023.05.017_bib19","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.05.017_bib20","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1182\/blood-2021-146100","article-title":"Safety and efficacy profile of autologous CD30.CAR-T-Cell therapy in patients with relapsed or refractory classical Hodgkin lymphoma (CHARIOT trial)","volume":"138","author":"Ahmed","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.05.017_bib21","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13045-018-0677-2","article-title":"Universal CARs, universal T\u00a0cells, and universal CAR-T cells","volume":"11","author":"Zhao","year":"2018","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.hoc.2023.05.017_bib22","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez Bedoya D., Dutoit V. and Migliorini D., Allogeneic CAR-T Cells: An Alternative to Overcome Challenges of CAR-T Cell Therapy in Glioblastoma, Front Immunol, 2021;12:640082.","DOI":"10.3389\/fimmu.2021.640082"},{"key":"10.1016\/j.hoc.2023.05.017_bib23","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u201cOff-the-shelf\u201d allogeneic CAR-T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.hoc.2023.05.017_bib24","doi-asserted-by":"crossref","first-page":"1067289","DOI":"10.3389\/fonc.2023.1067289","article-title":"Advances in the treatment of Hodgkin lymphoma: Current and future approaches","volume":"13","author":"Ullah","year":"2023","journal-title":"Front Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2023.05.017_bib25","first-page":"197","article-title":"The Emerging Role of CAR T Cell Therapy in Relapsed\/Refractory Hodgkin Lymphoma","volume":"12","author":"Meier","year":"2022","journal-title":"J\u00a0Pers Med"},{"issue":"25","key":"10.1016\/j.hoc.2023.05.017_bib26","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1182\/blood-2009-03-209650","article-title":"T\u00a0lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model","volume":"113","author":"Di Stasi","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.05.017_bib27","doi-asserted-by":"crossref","DOI":"10.1111\/his.14910","article-title":"CD30 expression is frequently decreased in relapsed classic Hodgkin lymphoma after anti-CD30 CAR T-cell therapy","author":"Marques-Piubelli","year":"2023","journal-title":"Histopathology"},{"issue":"4","key":"10.1016\/j.hoc.2023.05.017_bib28","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1182\/bloodadvances.2021005385","article-title":"Pretherapy metabolic tumor volume is associated with response to CD30 CAR T\u00a0cells in Hodgkin lymphoma","volume":"6","author":"Voorhees","year":"2022","journal-title":"Blood Adv"},{"issue":"25","key":"10.1016\/j.hoc.2023.05.017_bib29","doi-asserted-by":"crossref","first-page":"6756","DOI":"10.1182\/blood-2010-05-231548","article-title":"Peripheral T-cell lymphoma","volume":"117","author":"Foss","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.05.017_bib30","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","article-title":"CD7-edited T\u00a0cells expressing a CD7-specific CAR for the therapy of T-cell malignancies","volume":"130","author":"Gomes-Silva","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2023.05.017_bib31","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","article-title":"An \"off-the-shelf\" fratricide-resistant CAR-T for the treatment of T\u00a0cell hematologic malignancies","volume":"32","author":"Cooper","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2023.05.017_bib32","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1182\/bloodadvances.2017009928","article-title":"Blockade of CD7 expression in T\u00a0cells for effective chimeric antigen receptor targeting of T-cell malignancies","volume":"1","author":"Png","year":"2017","journal-title":"Blood Adv"},{"issue":"13","key":"10.1016\/j.hoc.2023.05.017_bib33","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1158\/1078-0432.CCR-21-4097","article-title":"Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia\/Lymphoma","volume":"28","author":"Zhang","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.hoc.2023.05.017_bib34","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ymthe.2022.09.003","article-title":"Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T\u00a0cells for T\u00a0cell malignancies","volume":"31","author":"Watanabe","year":"2023","journal-title":"Mol Ther"},{"issue":"8","key":"10.1016\/j.hoc.2023.05.017_bib35","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1182\/blood-2015-02-629527","article-title":"A\u00a0T-Cell-Directed chimeric antigen receptor for the selective treatment of T-cell malignancies","volume":"126","author":"Mamonkin","year":"2015","journal-title":"Blood"},{"issue":"10168","key":"10.1016\/j.hoc.2023.05.017_bib36","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"ECHELON-2 Study Group. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.hoc.2023.05.017_bib37","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1182\/blood.V77.7.1546.1546","article-title":"Stages of T-cell receptor protein expression in T-cell acute lymphoblastic leukemia","volume":"77","author":"Campana","year":"1991","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2023.05.017_bib38","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1182\/blood.V68.3.752.752","article-title":"Monoclonal antibody T101 in T\u00a0cell malignancies: a clinical, pharmacokinetic, and immunologic correlation","volume":"68","author":"Bertram","year":"1986","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2023.05.017_bib39","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1182\/blood.V78.5.1173.1173","article-title":"Phase I trial of H65-RTA immunoconjugate in patients with cutaneous T-cell lymphoma","volume":"78","author":"LeMaistre","year":"1991","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.hoc.2023.05.017_bib40","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood-2019-129559","article-title":"Safety and anti-tumor activity of CD5 car T-cells in patients with Relapsed\/Refractory T-cell malignancies","volume":"134","author":"Hill","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2023.05.017_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2019.12.482","article-title":"CD5 CAR T-Cells for Treatment of Patients with Relapsed\/Refractory CD5 Expressing T-Cell Lymphoma Demonstrates Safety and Anti-Tumor Activity","volume":"26","author":"Hill","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2023.05.017_bib42","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1182\/blood-2021-154142","article-title":"Early Signals of Anti-Tumor Efficacy and Safety with Autologous CD5.CAR T-Cells in Patients with Refractory\/Relapsed T-Cell Lymphoma","volume":"138","author":"Rouce","year":"2021","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.hoc.2023.05.017_bib43","doi-asserted-by":"crossref","first-page":"7028","DOI":"10.1200\/JCO.2022.40.16_suppl.7028","article-title":"Phase I study of donor-derived CD5 CAR T\u00a0cells in patients with relapsed or refractory T-cell acute lymphoblastic leukemia","volume":"40","author":"Pan","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2023.05.017_bib44","doi-asserted-by":"crossref","first-page":"967754","DOI":"10.3389\/fonc.2022.967754","article-title":"Chimeric antigen receptor T-cell therapy for T-ALL and AML","volume":"12","author":"Wei","year":"2022","journal-title":"Front Oncol"},{"issue":"3\u20134","key":"10.1016\/j.hoc.2023.05.017_bib45","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3109\/10428199709051778","article-title":"Therapy of patients with T-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin A chain immunotoxin","volume":"26","author":"Frankel","year":"1997","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.hoc.2023.05.017_bib46","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41408-023-00822-w","article-title":"Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies","volume":"13","author":"Zhang","year":"2023","journal-title":"Blood Cancer J"},{"issue":"11","key":"10.1016\/j.hoc.2023.05.017_bib47","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","article-title":"Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed\/refractory CD7-positive hematological malignancies: a phase I clinical study","volume":"32","author":"Hu","year":"2022","journal-title":"Cell Res"},{"issue":"4","key":"10.1016\/j.hoc.2023.05.017_bib48","first-page":"321","article-title":"Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL\/LBL: first-in-human phase 1 clinical trial","volume":"140","author":"Lu","year":"2022","journal-title":"Blood"},{"issue":"30","key":"10.1016\/j.hoc.2023.05.017_bib49","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1200\/JCO.21.00389","article-title":"Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial","volume":"39","author":"Pan","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"10.1016\/j.hoc.2023.05.017_bib50","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.hoc.2023.05.017_bib51","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/nm.4444","article-title":"Targeting the T cell receptor beta-chain constant region for immunotherapy of T cell malignancies","volume":"23","author":"Maciocia","year":"2017","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.hoc.2023.05.017_bib52","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1002\/acg2.54","article-title":"CAR-T cell Therapy for Non-Hodgkin Lymphomas: A New Treatment Paradigm","volume":"2","author":"Hill","year":"2019","journal-title":"Adv Cell Gene Ther"}],"updated-by":[{"DOI":"10.1016\/j.hoc.2023.11.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000}}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858823000722?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858823000722?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T21:51:43Z","timestamp":1700862703000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858823000722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S0889858823000722"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2023.05.017","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.hoc.2023.11.001","asserted-by":"object"}]},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric Antigen Receptor T Cells in Hodgkin and T-Cell Lymphomas","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2023.05.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}